ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...